Accelerate Diagnostics Inc. (NASDAQ:AXDX)’s share price dropped 3.7% on Friday . The company traded as low as $22.15 and last traded at $22.17, with a volume of 173,902 shares changing hands. The stock had previously closed at $23.02.

AXDX has been the subject of a number of analyst reports. BTIG Research reissued a “buy” rating and issued a $26.00 price objective on shares of Accelerate Diagnostics in a research report on Sunday, May 15th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $25.00 price objective on shares of Accelerate Diagnostics in a research report on Monday, May 16th. JPMorgan Chase & Co. boosted their price objective on shares of Accelerate Diagnostics from $17.00 to $25.00 and gave the company an “overweight” rating in a research report on Tuesday, August 9th. Finally, Zacks Investment Research lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 13th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $25.33.

The company’s market capitalization is $1.16 billion. The company has a 50-day moving average of $19.87 and a 200 day moving average of $14.79.

In related news, Director Jack W. Schuler bought 14,033 shares of the stock in a transaction on Tuesday, June 14th. The shares were purchased at an average price of $13.67 per share, with a total value of $191,831.11. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jack W. Schuler bought 88,316 shares of the stock in a transaction on Friday, June 10th. The shares were bought at an average cost of $14.69 per share, for a total transaction of $1,297,362.04. The disclosure for this purchase can be found here.

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that improve patient outcomes and lower healthcare costs through the diagnosis of serious infections. The Company’s technology platform is built to address these challenges by delivering testing of infectious pathogens in various patient sample types.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.